DOSAGE & ADMINISTRATION SECTION
DIRECTIONS: Place one patch on the body, using one of the locations shown in our instructions or the location of your choice.
DIRECTIONS: Place one patch on the body, using one of the locations shown in our instructions or the location of your choice.
Water, glycerol, citric acid, potassium sorbate, carnitine
WARNINGS: Remove immediately if you feel discomfort or skin irritation occurs. Do not reuse patch once removed from the skin.
For external use only. Do not ingest. Do not use more than one set of patches at a time on the body. Do not use on wounds or
damaged skin. Ask a health professional before using if you have a health condition.
Abrotanum, Anacardium, Arsenicum Alb, Baryta Carb, Baryta Mur, Calc Carb, Calc Fluor, Calc Phos, Ferrum Met, Fucus, Hekla, Hellebor Nig, Ignatia, Lycopodium, Nicotinamidum, Secale, Silicea
For the stimulation of acupuncture points.
Keep out of reach of children.
Do not use if pregnant or nursing.
For the stimulation of acupuncture points
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 76335-007-30 | 2023-10-30 | C162847 | 48780-1 | 9d75b9d0-76c6-f424-e053-dadaa90a57ce | dddcf6ae-c803-45d8-ba3b-946f3a548b85 |
| 76335-007-30 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-76c6-f424-e053-dadaa90a57ce | dddcf6ae-c803-45d8-ba3b-946f3a548b85 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARSENIC TRIOXIDE | ACTIVE INGREDIENT | S7V92P67HO | 2 | |
| ARTEMISIA ABROTANUM FLOWERING TOP | ACTIVE INGREDIENT | QG07G580U0 | 2 | |
| BARIUM CARBONATE | ACTIVE INGREDIENT | 6P669D8HQ8 | 2 | |
| BARIUM CHLORIDE DIHYDRATE | ACTIVE INGREDIENT | EL5GJ3U77E | 2 | |
| CALCIUM FLUORIDE | ACTIVE INGREDIENT | O3B55K4YKI | 2 | |
| CALCIUM PHOSPHATE | ACTIVE INGREDIENT | 97Z1WI3NDX | 2 | |
| CLAVICEPS PURPUREA SCLEROTIUM | ACTIVE INGREDIENT | 01G9XEA93N | 2 | |
| FUCUS VESICULOSUS | ACTIVE INGREDIENT | 535G2ABX9M | 2 | |
| HEKLA LAVA | ACTIVE INGREDIENT | C21158IIRK | 2 | |
| HELLEBORUS NIGER ROOT | ACTIVE INGREDIENT | 608DGJ6815 | 2 | |
| IRON | ACTIVE INGREDIENT | E1UOL152H7 | 2 | |
| LYCOPODIUM CLAVATUM SPORE | ACTIVE INGREDIENT | C88X29Y479 | 2 | |
| NIACINAMIDE | ACTIVE INGREDIENT | 25X51I8RD4 | 2 | |
| OYSTER SHELL CALCIUM CARBONATE, CRUDE | ACTIVE INGREDIENT | 2E32821G6I | 2 | |
| SEMECARPUS ANACARDIUM JUICE | ACTIVE INGREDIENT | Y0F0BU8RDU | 2 | |
| SILICON DIOXIDE | ACTIVE INGREDIENT | ETJ7Z6XBU4 | 2 | |
| STRYCHNOS IGNATII SEED | ACTIVE INGREDIENT | 1NM3M2487K | 2 | |
| ARSENIC CATION (3+) | ACTIVE MOIETY | C96613F5AV | 2 | |
| ARTEMISIA ABROTANUM FLOWERING TOP | ACTIVE MOIETY | QG07G580U0 | 2 | |
| BARIUM CATION | ACTIVE MOIETY | V645272HLN | 2 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 2 | |
| CLAVICEPS PURPUREA SCLEROTIUM | ACTIVE MOIETY | 01G9XEA93N | 2 | |
| FLUORIDE ION | ACTIVE MOIETY | Q80VPU408O | 2 | |
| FUCUS VESICULOSUS | ACTIVE MOIETY | 535G2ABX9M | 2 | |
| HEKLA LAVA | ACTIVE MOIETY | C21158IIRK | 2 | |
| HELLEBORUS NIGER ROOT | ACTIVE MOIETY | 608DGJ6815 | 2 | |
| IRON | ACTIVE MOIETY | E1UOL152H7 | 2 | |
| LYCOPODIUM CLAVATUM SPORE | ACTIVE MOIETY | C88X29Y479 | 2 | |
| NIACINAMIDE | ACTIVE MOIETY | 25X51I8RD4 | 2 | |
| OYSTER SHELL CALCIUM CARBONATE, CRUDE | ACTIVE MOIETY | 2E32821G6I | 2 | |
| SEMECARPUS ANACARDIUM JUICE | ACTIVE MOIETY | Y0F0BU8RDU | 2 | |
| SILICON DIOXIDE | ACTIVE MOIETY | ETJ7Z6XBU4 | 2 | |
| STRYCHNOS IGNATII SEED | ACTIVE MOIETY | 1NM3M2487K | 2 | |
| CARNITINE | INACTIVE INGREDIENT | S7UI8SM58A | 2 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 2 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 76335-007 | 76335-007-30 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / TOPICAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION, EXTENDED RELEASE / ORAL | 140.8 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, EXTENDED RELEASE / ORAL | 265 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SPRAY / NASAL | 9 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / OPHTHALMIC | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRA-ARTICULAR | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SHAMPOO / TOPICAL | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / BUCCAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, CHEWABLE / ORAL | 7 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CAPSULE / ORAL | 238 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | FILM, EXTENDED RELEASE / TRANSDERMAL | 1.38 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | MOUTHWASH / BUCCAL | 100 mg/1ml | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / RESPIRATORY (INHALATION) | 0.03 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, ORALLY DISINTEGRATING / ORAL | 83 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CREAM / TOPICAL | 4 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CAPSULE, EXTENDED RELEASE / ORAL | 101 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER / ORAL | 840 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | FILM / SUBLINGUAL | 10 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CONCENTRATE / ORAL | 5.3 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / VAGINAL | 60 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, FILM COATED / ORAL | 42 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / EPIDURAL | 0.02 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / ORAL | 315 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / OPHTHALMIC | 3 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, COATED / ORAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / TOPICAL | 17 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TROCHE / ORAL | 12 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / AURICULAR (OTIC) | 0.2 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / RESPIRATORY (INHALATION) | 8 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET / SUBLINGUAL | 24 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRAMUSCULAR | 26 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SPRAY, METERED / NASAL | 2 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 08f44b7e-8941-2130-e063-6394a90a6fd4 | dddcf6ae-c803-45d8-ba3b-946f3a548b85 | 2023-10-30 | Warnings | dddcf6ae-c803-45d8-ba3b-946f3a548b85 |
Adverse event summaries are temporarily unavailable. Other product information remains available.